Comment on "Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients"

J Cyst Fibros. 2020 Sep;19(5):839. doi: 10.1016/j.jcf.2020.04.009. Epub 2020 Jun 2.

Authors

Manfred Ballmann¹, Nicole Prinz², Aenne Glass³, Reinhard Holl²

Affiliations

¹ University Medicine Pediatric Clinic Ernst Heydemann Strasse 8 18057 Rostock Germany. Electronic address: Manfred.Ballmann@Med.Uni-Rostock.de.
² University Ulm, Institute for epidemiology and medical biometry Albert-Einstein-Allee 41 89081 Ulm Germany.
³ University Medicine Rostock Institute for Biostatistics and Informatic in Medicine and age research (IBIMA) Ernst Heydemann Strasse 8 18057 Rostock, Germany.

PMID: 32507542
DOI: 10.1016/j.jcf.2020.04.009

No abstract available

Publication types

Letter
Comment

MeSH terms

Aminophenols
Aminopyridines / adverse effects
Benzodioxoles / adverse effects
Cystic Fibrosis* / drug therapy
Glucose
Humans
Quinolones

Substances

Aminophenols
Aminopyridines
Benzodioxoles
Quinolones
ivacaftor
lumacaftor
Glucose